# Filing Detail

Form DRS - Draft Registration Statement:
SEC Accession No. 0000950123-24-006286
Filing Date
2024-06-21
Accepted
2024-06-21 17:14:49
Documents
28

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | filename1.htm | DRS | 1851174
2 |  | filename2.htm | EX-3.1 | 130911
3 |  | filename3.htm | EX-3.3 | 71893
4 |  | filename4.htm | EX-4.2 | 215665
5 |  | filename5.htm | EX-4.3 | 52780
6 |  | filename6.htm | EX-10.2 | 307682
7 |  | filename7.htm | EX-10.3 | 363255
8 |  | filename8.htm | EX-10.7 | 38396
9 |  | filename9.htm | EX-10.8 | 49558
10 |  | filename10.htm | EX-10.10 | 178980
11 |  | filename11.htm | EX-10.11 | 354015
12 | GRAPHIC | g769642g01p52.jpg | GRAPHIC | 30931
13 | GRAPHIC | g769642g05f43.jpg | GRAPHIC | 601719
14 | GRAPHIC | g769642g30x67.jpg | GRAPHIC | 36350
15 | GRAPHIC | g769642g31l38.jpg | GRAPHIC | 50551
16 | GRAPHIC | g769642g55a01.jpg | GRAPHIC | 52982
17 | GRAPHIC | g769642g55f74.jpg | GRAPHIC | 58099
18 | GRAPHIC | g769642g62f25.jpg | GRAPHIC | 64074
19 | GRAPHIC | g769642g66t55.jpg | GRAPHIC | 32846
20 | GRAPHIC | g769642g72h13.jpg | GRAPHIC | 35890
21 | GRAPHIC | g769642g72u41.jpg | GRAPHIC | 29072
22 | GRAPHIC | g769642g76l04.jpg | GRAPHIC | 54832
23 | GRAPHIC | g769642g77q77.jpg | GRAPHIC | 33838
24 | GRAPHIC | g769642g81q05.jpg | GRAPHIC | 40409
25 | GRAPHIC | g769642g94f07.jpg | GRAPHIC | 55303
26 | GRAPHIC | g769642g96l94.jpg | GRAPHIC | 67135
27 | GRAPHIC | g769642g98g45.jpg | GRAPHIC | 43304
28 | GRAPHIC | g769642g98o36.jpg | GRAPHIC | 31282
| Complete submission text file | 0000950123-24-006286.txt |  | 5425429

Mailing Address 171 OYSTER POINT BOULEVARD, SUITE 300 SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BOULEVARD, SUITE 300 SAN FRANCISCO CA 94080 6508505070
Maze Therapeutics, Inc. (Filer) CIK: 0001842295 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DRS | Act: 33 | File No.: 377-07295 | Film No.: 241061372
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)